DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?

Cancer Discov. 2016 Feb;6(2):130-2. doi: 10.1158/2159-8290.CD-15-1321.

Abstract

Precision treatment with targeted cancer drugs requires the selection of patients who are most likely to benefit from a given therapy. We argue here that the use of a combination of both DNA and transcriptome analyses will significantly improve drug response prediction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Molecular Targeted Therapy
  • Mutation*
  • Neoplasms / drug therapy*
  • Neoplasms / genetics*
  • Patient Selection
  • Precision Medicine
  • Sequence Analysis, DNA
  • Sequence Analysis, RNA
  • Treatment Outcome

Substances

  • Antineoplastic Agents